Dr. med. Melanie Hagen

Lehrstuhl für Innere Medizin III Department of Medicine 3 – Rheumatology and Immunology

Deep phenotyping of skin tissue remodeling in patients with systemic sclerosis treated with CD19-CAR T cells (2026) Rius Rigau AR, Xu M, Liu Z, Chenguiti Fakhouri S, Auth J, Garantziotis P, Zoli A, et al. Journal article Low-dose blinatumomab in multidrug-resistant rheumatoid arthritis—a case series (2026) Bucci L, Hagen M, Böltz S, Tur C, Nöthling DM, Dashi T, Auth J, et al. Journal article The why, what, who and when of B cell depletion in systemic lupus erythematosus: biological rationale, patient stratification and evolving therapeutic modalities (2026) Wincup C, Gatto M, Scherlinger M, Schett G, Hagen M Journal article, Review article Hormone levels of female patients with SLE after anti-CD19 CAR T-cell treatment do not indicate a signal of impaired ovarian reserve (2026) Pecher AC, Henes J, Henes M, Lengerke C, Bethge W, Wirsching A, Rothe T, et al. Journal article Progress and promise of CAR-T cell treatment in autoimmune diseases (2026) Bachl J, Hagen M, Schett G Journal article Real-world longitudinal assessment of anifrolumab in patients with systemic lupus erythematosus: clinical outcomes, safety and modulation of cytokines and neutrophil activity (2026) Temiz A, Noversa de Sousa R, Schoen J, Reichardt C, Standfest K, Wirsching A, Hagen M, et al. Journal article Bispecific T cell engagers for treatment-refractory autoimmune connective tissue diseases (2026) Düsing C, Györfi AH, Stütz AN, Lahu LM, Deicher FS, Li YN, Bruch PM, et al. Journal article BCMA T-Cell Engager Therapy in Patients with Refractory Autoimmune Disease (2025) Bucci L, Böltz S, Hagen M, Tur C, Nöthling DM, Rothe T, Wirsching A, et al. Journal article Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with refractory systemic lupus erythematosus – Authors' reply (2025) Hagen M, Müller F, Wirsching A, Kharboutli S, Spörl S, Düsing C, Krickau T, et al. Journal article BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells (2025) Müller F, Wirsching A, Hagen M, Völkl S, Tur C, Raimondo MG, Taubmann J, et al. Journal article